Acceleris are pleased to announce that BiVictriX Therapeutics (“BVX”) have closed a placing of £0.2m from existing and new shareholders. This is part of a planned larger overall raise aiding the company in further progressing its lead asset which has started to build substantial interest in the sector.
BVX, an existing client company of Acceleris, is a cutting-edge biotech which employs a revolutionary new approach, Bi-Cygni®, to the reduce the toxicity associated with cancer therapeutics. This ensures patients can receive higher doses of treatment to effectively eradicate the cancer, without harming the patient in the process. Acceleris has advised and supported the company since inception, with 2019 seeing the Company achieving highly encouraging early animal data, validating the concept in a particularly aggressive form of blood cancer, Acute Myeloid Leukaemia. The Company is now well positioned to take the lead asset forward with the aim of securing an early collaboration with industry, together with expanding its increasing pipeline of future assets.